Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Immunological aspects of Graves' disease patients in different clinical stages.

Gauna A, Segura G, Sartorio G, Soto R, Segal-Eiras A.

J Endocrinol Invest. 1989 Nov;12(10):671-7.

PMID:
2614006
2.

[The role of circulating immune complexes in the pathogenesis of Graves' disease].

Funauchi M.

Nihon Naibunpi Gakkai Zasshi. 1983 Dec 20;59(12):1912-27. Japanese.

PMID:
6325260
3.

Quantitative immunological differences between newly diagnosed Graves' disease patients and relapsed patients.

Di Mario U, Cavatorta FP, Perfetti R, Pugliese G, Pozzilli P, Sutherland J, Vitillo M, Andreani D.

J Endocrinol Invest. 1988 Feb;11(2):85-9.

PMID:
3258878
4.

Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.

Tamaki H, Amino N, Iwatani Y, Tachi J, Kimura M, Mitsuda N, Ichihara K, Tanizawa O, Miyai K.

Clin Endocrinol (Oxf). 1989 May;30(5):493-503.

PMID:
2575017
5.

Humoral and cellular immunological factors as possible markers of clinical relapse in HLA-typed Graves' patients followed with time.

Di Mario U, Vitillo M, Perfetti R, Mancuso M, Morellini M, Cappellacci S, Pozzilli P, Andreani D.

Horm Metab Res. 1989 May;21(5):267-71.

PMID:
2789166
6.

[Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].

Rink T, Holle LH, Schroth HJ, Garth H.

Nuklearmedizin. 1998 May;37(3):90-4. German.

PMID:
9604228
7.
8.

Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.

Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K.

J Endocrinol Invest. 1997 Sep;20(8):452-61.

PMID:
9364248
9.
11.

[TSH anti-receptor antibodies in Graves' disease].

Sérgio MR, Godinho C, Guerra L, Agapito A, Fonseca F, Costa C.

Acta Med Port. 1996 Jul-Sep;9(7-9):229-31. Portuguese.

12.

Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.

Aizawa T, Ishihara M, Koizumi Y, Hashizume K, Takasu N, Yamada T, Kobayashi I, Watanabe T, Shimizu Z.

Am J Med. 1990 Aug;89(2):175-80.

PMID:
2166430
13.

Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.

Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Rosei EA.

Endocr J. 2007 Dec;54(5):713-20. Epub 2007 Aug 3.

14.

Graves' disease: evolution and prognosis after eight months of treatment with methimazole.

Gauna AT, Guillén CE, Sartorio GC, Soto RJ.

Medicina (B Aires). 1992;52(3):207-12.

PMID:
1364158
15.

Thyrotropin receptor antibodies in black South African patients with Graves' disease and their response to medical therapy.

Zouvanis M, Panz VR, Kalk WJ, Joffe BI.

J Endocrinol Invest. 1998 Dec;21(11):771-4.

PMID:
9972678
16.
17.

[Evaluation of immunological tests in thyroid diseases].

Hirooka Y, Mitsuma T.

Rinsho Byori. 1991 Sep;39(9):920-5. Japanese.

PMID:
1942565
18.

Interleukin-21 is associated with disease activity in patients with Graves' disease.

Zhang J, Zeng H, Ren M, Yan H, Xu M, Feng Z, Liang W, Yang C, Cheng H, Ding H, Yan L.

Endocrine. 2014 Aug;46(3):539-48. doi: 10.1007/s12020-013-0105-x. Epub 2013 Nov 28.

PMID:
24287789
19.

Lymphocytes resided in the thyroid are the main source of TSH-receptor antibodies in Basedow's-Graves' disease?

Leövey A, Nagy E, Balazs G, Bako G.

Exp Clin Endocrinol. 1992;99(3):147-50.

PMID:
1526264
20.

Immunity in Graves' disease at diagnosis: correlation between activated T cells and humoral immune factors.

Di Mario U, Scardellato A, Irvine WJ, Kennedy L, Kadlubowski M, Kennedy R, Cavatorta FP, Andreani D.

Acta Endocrinol (Copenh). 1986 Dec;113(4):493-9.

PMID:
3491482

Supplemental Content

Support Center